Trial Profile
A retrospective study assessing safety and efficacy of Brentuximab vedotin followed by allogeneic stem-cell transplantation in patients with CD30 anaplastic or T-cell Non Hodgkin Lymphomas.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2016
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Allotransplant rejection; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 05 Feb 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology